bntx

$114.01
-$10.23 (-8.2%)
Closing price December 1, 2020
Tuesday's top analyst upgrades and downgrades included BioNTech, Charles Schwab, FedEx, First Solar, Micron Technologies, Nio, Occidental Petroleum, Salesforce.com, Square and Zoom Video...
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Shares of COVID-19 vaccine duo Pfizer and BioNTech made handy gains on Wednesday after they announced their late-stage coronavirus study had concluded.
Moderna reported a 95.4% effectiveness rate for its COVID-19 vaccine. This is the second vaccine to hit more than 90% efficacy in the past week.
Pfizer and BioNTech stocks both exploded on Monday after these companies provided an update on their coronavirus vaccine.
The novel coronavirus has wiped out trillions of dollars in global output with more than 1 million deaths worldwide in 2020. With cases rising rapidly in the United States and in Europe, more...
While other companies seem to be struggling with their coronavirus vaccines, Pfizer and BioNTech are just picking up speed. Pfizer’s CEO has provided an update on their COVID-19 vaccine.
Wednesday's top analyst upgrades and downgrades included Apple, BioNTech, Intel, Microsoft, Nio, Oracle, Peloton Interactive, Salesforce.com and Williams-Sonoma.
Many health care products become much more popular because of endorsements and advertising efforts. It is a longstanding practice that has come under fire by both political parties in the United...
The race for finding the COVID-19 vaccine is in full swing, and it has just seen one team move ahead of the others. Before getting into an actual prediction basis for knowing which vaccine (or...
Pfizer and BioNTech provided an update for their coronavirus vaccine that is currently in the late stages of development and testing.
Thursday's top analyst upgrades and downgrades included Costco, Enphase Energy, Etsy, Moderna, Novavax, Regeneron Pharmaceuticals, Roku, Square, Teva Pharmaceutical, Wayfair and Zynga.
Pfizer and BioNTech made another big step in their fight against COVID-19 by initiating their late-stage study for their lead mRNA vaccine candidate.
Pfizer and BioNTech S.E. aim to begin delivering 300 million doses of their vaccine for COVID-19 in 2021, but in the meantime, these companies will get a nice payoff.
BioNTech is one of the leading companies in the race to a COVID-19 vaccine. With its shares up more than 160% year to date, it’s time to capitalize.